Rahul Singhvi, Resilience CEO (Business Wire)

ARCH-backed Re­silience nabs its lat­est fi­nanc­ing round, putting to­geth­er a mas­sive $625M Se­ries D

Since emerg­ing from stealth in late 2020, Re­silience has me­thod­i­cal­ly built up its cash re­serves and inked nu­mer­ous col­lab­o­ra­tion deals. On Mon­day, the com­pa­ny an­nounced its lat­est move.

The Bob Nelsen-backed biotech re­vealed plans for its Se­ries D ear­ly Mon­day morn­ing, putting to­geth­er $625 mil­lion to fur­ther its mis­sion of be­com­ing the “Fox­conn” of biotech. Mon­day’s new cash will be used to con­tin­ue in­vest­ing in its in­fra­struc­ture through more deals, po­ten­tial ac­qui­si­tions and R&D ex­pan­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.